Sucampo (SCMP +0.6%) bucks a weak tape after saying that the Japanese Science and Technology Agency has adopted the company's unoprostone isopropyl ophthalmic solution into its Technology Transfer Program. As part of the program, Japanese development partner R-Tech Ueno has signed an agreement with the agency to provide the majority of funding for Phase 3 clinical development costs for its treatment of retinitis pigmentosa. SCMP is planning to file for FDA approval pending the successful trials.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs